Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs ; volume:73 ; number:10 ; day:9 ; month:8 ; year:2024 ; pages:1-17 ; date:10.2024
Cancer immunology immunotherapy ; 73, Heft 10 (9.8.2024), 1-17, 10.2024
- Creator
-
Guo, Cuicui
Dai, Xiaodong
Du, Yulei
Xiong, Xiumei
Gui, Xun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-024-03794-3
- URN
-
urn:nbn:de:101:1-2411292059392.842773732696
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Guo, Cuicui
- Dai, Xiaodong
- Du, Yulei
- Xiong, Xiumei
- Gui, Xun
- SpringerLink (Online service)
Other Objects (12)
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
CTLA-4 +49 G/A, a functional T1D risk SNP, affects CTLA-4 level in Treg subsets and IA-2A positivity, but not beta-cell function
Klinische Erforschung der CTLA-4-Insuffizienz
Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
CTLA-4 Insufficiency due to a Novel CTLA - 4 Deletion, Identified through Copy Number Variation Analysis
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Ausbildungsanleitung des CTLA/LaSK zum Trainer 9F616M1
Genetics, phenotype, and treatment of CTLA-4 insufficiency
The effect of CTLA-4 lg on B cells
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
CTLA-4 +49 G/A, a functional T1D risk SNP, affects CTLA-4 level in Treg subsets and IA-2A positivity, but not beta-cell function
Klinische Erforschung der CTLA-4-Insuffizienz
Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
CTLA-4 Insufficiency due to a Novel CTLA - 4 Deletion, Identified through Copy Number Variation Analysis
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Ausbildungsanleitung des CTLA/LaSK zum Trainer 9F616M1
Genetics, phenotype, and treatment of CTLA-4 insufficiency
The effect of CTLA-4 lg on B cells
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
CTLA-4 +49 G/A, a functional T1D risk SNP, affects CTLA-4 level in Treg subsets and IA-2A positivity, but not beta-cell function
Klinische Erforschung der CTLA-4-Insuffizienz
Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
CTLA-4 Insufficiency due to a Novel CTLA - 4 Deletion, Identified through Copy Number Variation Analysis
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
Ausbildungsanleitung des CTLA/LaSK zum Trainer 9F616M1
Genetics, phenotype, and treatment of CTLA-4 insufficiency
The effect of CTLA-4 lg on B cells